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Abstract Thiopurine therapy effectively maintains
remission in inflammatory bowel disease. However, many
patients are unable to achieve optimum benefits from
azathioprine or 6-mercaptopurine because of undesirable
metabolism related to high thiopurine methyltransferase
(TPMT) activity characterized by hepatic transaminitis
secondary to increased 6-methylmercaptopurine (6-MMP)
production and reduced levels of therapeutic 6-thioguanine
nucleotide (6-TGN). Allopurinol can optimize this skewed
metabolism. We discuss two brothers who were both
diagnosed with ulcerative colitis (UC). Their disease
remained active despite oral and topical mesalamines.
Steroids followed by 6-mercaptopurine (MP) were unsuc-
cessfully introduced for both patients and both were found
to have high 6-MMP and low 6-TGN levels, despite normal
TMPT enzyme activity, accompanied by transaminitis.
Allopurinol was introduced in combination with MP dose
reduction. For both brothers addition of allopurinol was
associated with successful remission and optimized MP
metabolites. These siblings with active UC illustrate that
skewed thiopurine metabolism may occur despite normal
TPMT enzyme activity and can lead to adverse events in
the absence of disease control. We confirm previous data
showing that addition of allopurinol can reverse this
skewed metabolism, and reduce both hepatotoxicity and
disease activity, but we now also introduce the concept of a
family history of preferential MP metabolism as a clue to
effective management for other family members.
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Introduction
Thiopurine therapy, including 6-mercaptopurine (MP) and
azathioprine, is a well-established steroid-sparing mainte-
nance strategy for inflammatory bowel disease (IBD).
However, many patients discontinue this therapy because
of lack of efficacy or intractable adverse events [1]. For
some of these patients thiopurine metabolism is skewed;
this is characterized by grossly increased levels of
6-methylmercaptopurine (6-MMP) and reduced levels of
the pharmacologically active 6-thioguanine nucleotides
(6-TGN) in red blood cells (RBC). This skewed 6-MMP/
6-TGN ratio is associated with hepatotoxicity (mainly
transaminitis), pancytopenia, and lack of therapeutic
response [2–5].
Thiopurine S-methyltransferase (TPMT) is an enzyme
that catalyzes the conversion of azathioprine and MP to
6-MMP. Genetic polymorphisms of TPMT have been
described and homozygous and heterozygous allelic vari-
ations occur in 0.3 and 5–15% of the general population,
respectively [6–9]. These genetic polymorphisms correlate
with TPMT enzyme activity and accurately predict
absent to low (homozygous genotype) and intermediate
(heterozygous genotype) levels of TPMT enzyme activity
[10, 11]. Low TPMT enzyme activity generally results in a
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reduced 6-MMP/6-TGN ratio, because thiopurines are
shunted to the therapeutic 6-TGN, leading to an increased
risk of myelotoxicity [12]. Conversely, a normal ‘‘wild-
type’’ TPMT genotype is predictive of normal to high
enzyme activity and these patients typically produce larger
amounts of 6-MMP, associated with a reduced likelihood
of achieving clinical remission [13, 14].
One strategy used to overcome this unfavorable meta-
bolic profile characterized by a high 6-MMP/6-TGN ratio
is addition of allopurinol to adjusted low-dose thiopurine
therapy. This combination therapy leads to increased for-
mation of 6-TGN and a decrease in 6-MMP levels. Several
studies have demonstrated that this strategy can optimize
thiopurine metabolism in IBD patients, with steroid-free
remission achieved in more patients and with reduced
adverse events [15–17].
In this case report we discuss two brothers diagnosed
with UC. Both had a high 6-MMP/6-TGN ratio despite
normal TPMT enzyme activity and regular weight-based
MP monotherapy. Addition of allopurinol combined with
reduction of MP dose led to full clinical remission and
resolution of liver test abnormalities. This case report
emphasizes the significance of optimization of thiopurine
therapy by allopurinol co-administration for IBD patients
with skewed metabolism, and further demonstrates the
potential familial nature of this metabolic pattern.
Cases
Patient A is a 22-year-old male who developed hemato-
chezia at the age of 16. Colonoscopy by his pediatrician
revealed diffuse inflammation of the large intestine with
more intense inflammation in the distal colon He responded
promptly to corticosteroid therapy, but his remission was
not durable despite therapy with oral and topical mesala-
mine. MP (50 mg) was initiated to enable steroid with-
drawal after normal TPMT enzyme activity (23.0 U/ml
RBC, normal [21 U/ml RBC) was demonstrated
(Table 1). However, during attempts to increase the dose of
MP, levels of alanine aminotransferase (ALT) reached a
maximum of 114 U/l (normal \35), without clinical signs
of adverse effects. Subsequent measurement of thiopurine
metabolites revealed high levels of 6-MMP of
13,477 pmol/8 9 108 RBC, whereas 6-TGN remained at
subtherapeutic levels (\235 pmol/8 9 108 RBC). Reduc-
tion of the MP dose to 75 mg resulted in normalization of
liver tests and lower levels of thiopurine metabolites
(6-TGN 137 and 6-MMP 3,700 pmol/8 9 108). In the next
year, the patient was not able to achieve steroid-free
remission with MP and oral and topical mesalamine.
Allopurinol 100 mg was introduced to skew the MP
metabolism toward higher 6-TGN levels and lower 6-MMP
levels. The dose of MP was reduced to 25 mg to prevent a
disproportionate increase in 6-TGN levels that could
potentially cause myelotoxicity. He responded well to this
strategy over the course of the following months. He
achieved full clinical remission in the absence of hepato-
toxicity or myelotoxicity and was able to discontinue cor-
ticosteroids. The dose of MP was increased to 50 mg daily
to obtain optimum levels of 6-TGN, on the basis of MP
metabolites. Recent measurement of thiopurine metabolites
showed a 6-TGN level of 422 pmol/8 9 108 RBC and
6-MMP was not quantifiable (lower detection level
255 pmol/8 9 108 RBC). On follow-up 14 months after
initiation of the combination therapy, he remains in stable,
steroid-free remission on allopurinol 100 mg and MP
50 mg.
Case B is a 19-year-old male and the younger brother of
the patient described in case A. In 2008, he was diagnosed
with mild-to-moderate ulcerative proctitis. Histology of
rectal biopsies showed moderately active colitis compatible
with UC. He improved on oral and topical mesalamine. In
the subsequent year his symptoms recurred, and an
increased dose of oral mesalamines, mesalamine enemas,
and short courses of corticosteroids resulted in temporary
clinical improvement only. Endoscopically, his proctitis
progressed to left-sided UC and he was admitted to our
IBD service. Intravenous administration of methylpred-
nisolone was initiated with only minimal clinical
improvement by day 5. Subsequently, he received a load-
ing dose of infliximab 5 mg/kg in order to induce remis-
sion. He noticed improvement of symptoms and was
discharged. However, he shortly had recurrence of his
symptoms and, despite escalation of the infliximab to
10 mg/kg and addition of hydrocortisone enemas, was
Table 1 Characteristics of thiopurine therapy for cases A and B
Case MP monotherapy MP/allopurinol
TPMT 6-TGN 6-MMP ALT 6-TGN 6-MMP ALT
A 23.0 137 13,477 114 422 NQ 21
B 19.7 301 12,796 141 351 NQ 25
MP, 6-mercaptopurine; TPMT, thiopurine methyltransferase, normal [21 U/ml RBC; 6-TGN, 6-thioguanine nucleotide, pmol/8 9 108 RBC;
6-MMP, 6-methylmercaptopurine, pmol/8 9 108 RBC; ALT, alanine aminotransferase, normal \35 U/l; NQ, not quantifiable
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unable to achieve symptom control. Infliximab was dis-
continued because of the absence of clinical benefit. His
TMPT was determined at 19.7 U/ml RBC and MP was
initiated at approximately 1.5 mg/kg. Within a few weeks
after initiation of this thiopurine therapy, his symptoms
continued and we noticed elevation of his ALT to 141 U/l.
The MP metabolites were determined and showed a 6-TGN
level of 301 and elevated 6-MMP levels (12,796 pmol/
8 9 108 RBC). Subsequently, the dose of MP was reduced
to 25 mg and allopurinol 100 mg per day was started. He
promptly responded to allopurinol with shunting of his
thiopurine metabolites toward the formation of 6-TGN
(351 pmol/8 9 108 RBC) and undetectable 6-MMP levels,
which clinically corresponded with complete resolution of
his transaminitis. He rapidly achieved stable remission with
this strategy. We continue to follow him and he has cur-
rently been in stable remission for 8 months, maintained by
MP 50 mg and allopurinol 100 mg per day.
Discussion
In this report we discuss two siblings who were diagnosed
with UC at a young age. The subsequent course of their
disease and the therapy required were remarkably similar.
They both had steroid-dependent disease and required
steroid-sparing maintenance strategy. After introduction of
MP, they had a skewed 6-MMP/6-TNG ratio with trans-
aminitis and poor disease control. Full clinical remission of
UC was achieved with resolution of earlier liver test
abnormalities after optimizing thiopurine therapy by
addition of allopurinol to low-dose MP.
Rundles and others have demonstrated that addition of
allopurinol increased the bioavailability of MP [18].
However, myelotoxicity frequently occurred with this
combination therapy and, subsequently, allopurinol was
mainly used for treatment of gout. Combination therapy
with thiopurines and allopurinol was used again in trans-
plantation medicine to optimize immunosuppression in
renal transplant patients [19]. In the last decade, our group
and other groups have reported clinical benefit from addi-
tion of allopurinol to dose-adjusted thiopurine therapy in
IBD patients. Although small in size, these series have
demonstrated a clinically relevant optimization of the
skewed 6-MMP/6-TGN ratio [15–17]. This combination
therapy is associated with steroid-free remission, and with
reduction in transaminitis corticosteroid dosing and non-
hepatic adverse events that occurred in IBD patients on
thiopurine monotherapy [15–17].
It is unclear by which mechanism allopurinol improves
thiopurine metabolism. One potential mechanism is inhi-
bition of TPMT through 6-thioxanthine (6-TX), as dem-
onstrated in in-vitro studies in RBC [20]. This is an
attractive explanation because allopurinol facilitates the
production of 6-TX when combined with low-dose
thiopurines. Alternatively, oxypurinol metabolites, which
antagonize TPMT, may be involved [21]. The outcomes of
in-vitro studies are, unfortunately, limited, because inhib-
itory metabolites are washed off during the TPMT assay.
Therefore, in-vivo studies are required to test these
hypotheses and to seek alternative pathways in IBD
patients. The results of these two cases suggest the mech-
anism of preferential 6-MMP shunting may have a genet-
ically determined origin.
High TPMT enzyme activity (wild type) generally
results in reduced availability of MP for 6-TGN generation,
because of rapid methylation of MP to 6-MMP. These
patients have difficulty achieving therapeutic 6-TGN levels
and tend to develop high levels of 6-MMP with the
attendant higher risk of transaminitis. We determined
TPMT enzyme activity for both siblings in this case report;
their TPMT enzyme activity was in the low-normal range
and they still developed elevated levels of methylated
metabolites of MP. TPMT genotyping was not available for
the patients in our case report. However, it is unlikely that
their skewed thiopurine metabolism is the result of previ-
ously described allelic TPMT variations that would lead to
a homozygous or heterozygous TPMT genotype given their
similar normal rather than low to absent TPMT enzyme
activity and excellent phenotype-genotype correlation for
this group of patients in the literature [10, 11]. Alterna-
tively, allelic variations correlating with high TPMT
enzyme activity and resulting high 6-MMP levels have
been described but do not apply to our patients because
they had low-normal rather than high TPMT enzyme
activity [22].
The familial aspect of skewed thiopurine metabolism
with a high 6-MMP/6-TGN ratio as presented in this report
is rare. In previously published cases familial genetic
variations led to altered TPMT enzyme activity in multiple
family members, but these were only cases with reduced to
absent TPMT enzyme activity [23, 24]. As far as we are
aware, no hereditary pattern associated with a high
6-MMP/6-TGN ratio has yet been reported.
The finding of skewed thiopurine metabolism despite
normal TPMT enzyme activity is not uncommon. In our
yet unpublished cohort at the University of Chicago that
included a subgroup of 26 IBD patients with a high
6-MMP/6-TGN ratio, 19 (73%) patients had low to normal
TPMT enzyme activity. In this group of patients, and the
patients discussed in this case report, TPMT status has poor
predictive value for therapeutic efficacy and adverse events
and recent studies confirm our observations. For example,
TPMT enzyme activity was not predictive of treatment
outcome a in a recent prospective trial in 113 IBD patients
who started thiopurine therapy [25]. Furthermore, in both
252 Dig Dis Sci (2012) 57:250–253
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the latter study and a recent meta analysis, TPMT status
was not predictive of transaminitis [10, 25]. Thus, TPMT
status has limitations as a predictor of thiopurine metabo-
lism, clinical efficacy, and adverse events.
In conclusion, we discuss two siblings who developed
transaminitis and therapeutic failure, despite low-normal
TPMT enzyme activity, when exposed to normal weight-
based MP for active UC. Addition of allopurinol and
reduction of MP dose led to normalization of the 6-MMP/
6-TGN ratio and liver test abnormalities, and steroid-free
remission was achieved for both siblings. This is the first
report of a familial skewed MP metabolism of this pattern
and is indicative of underlying genetic determination of
this metabolism, possibly similar to the well described
TPMT polymorphism.
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